Rhumbline Advisers bought a new stake in shares of Covetrus Inc (NASDAQ:CVET) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 237,131 shares of the company’s stock, valued at approximately $2,819,000. Rhumbline Advisers owned 0.21% of Covetrus as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of CVET. Macquarie Group Ltd. bought a new position in Covetrus during the 2nd quarter valued at about $30,000. M&R Capital Management Inc. bought a new position in Covetrus during the 3rd quarter valued at about $59,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Covetrus during the 3rd quarter valued at about $73,000. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Covetrus during the 3rd quarter valued at about $90,000. Finally, Ridgewood Investments LLC bought a new position in Covetrus during the 3rd quarter valued at about $129,000. Institutional investors and hedge funds own 91.73% of the company’s stock.
In other Covetrus news, insider Erin Powers Brennan purchased 1,684 shares of Covetrus stock in a transaction dated Wednesday, August 21st. The stock was purchased at an average price of $14.90 per share, with a total value of $25,091.60. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ CVET traded up $2.35 during midday trading on Tuesday, hitting $12.40. 77,065 shares of the company’s stock traded hands, compared to its average volume of 3,663,771. Covetrus Inc has a 1 year low of $8.16 and a 1 year high of $43.83. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.74 and a quick ratio of 0.91. The firm has a fifty day moving average of $10.64 and a 200 day moving average of $19.88.
Covetrus (NASDAQ:CVET) last released its quarterly earnings results on Tuesday, August 13th. The company reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.05 billion. Equities research analysts anticipate that Covetrus Inc will post 0.42 earnings per share for the current year.
Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
Featured Article: What strategies should day traders use to execute a trade?
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.